Skip to main content

Advertisement

Log in

Zoledronic acid and bone cellular respiration

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Phosphorescence O2 analyzer was used to measure calvarial bone cellular respiration (cellular mitochondrial O2 consumption) in Taylor Outbred mice in the presence and absence of zoledronic acid. This potent bisphosphonate inhibits osteoclast-mediated calcium resorption, and its effects on bone respiration have not been previously investigated. The change of O2 concentration with time was measured in closed vials containing phosphate-buffered saline (PBS), 5 mM glucose and 5–25 mg calvarial bone fragments, and it was complex for t = 0–30 h. Cyanide (specific inhibitor of cytochrome oxidase) halted O2 consumption, confirming the oxidation occurred in the respiratory chain. Initial rate of respiration was estimated from the zero-order plots d[O2]/dt for t = 0–4 h. For untreated specimens, the rate (mean ± SD) was 2.0 ± 1.2 µM O2 h−1 mg−1 (n = 6). This value was 7–10 times lower than that of other murine organs, but similar to that reported for rat and Guinea pig calvaria (averaging, 2.7 nmol O2 h−1 mg−1). The corresponding rate in the presence of 10–100 µM zoledronic acid was 2.7 ± 0.7 µM O2 h−1 mg−1 (n = 11), p = 0.216. The first-order plots ln ([O2] t  ÷ [O2] t=0) versus time for t = 0–30 h were also used to compare treated and untreated specimens. The rate (h−1 mg−1 103) for specimens incubated in PBS without glucose was 1.3 ± 0.6 (n = 3, p = 0.007), in PBS + glucose it was 10.7 ± 6.9 (n = 10), in PBS + glucose + 10 µM zoledronic acid it was 12.1 ± 6.7 (n = 10, p = 0.579), in PBS + glucose + 20 µM zoledronic acid it was 12.9 ± 3.3 (n = 9, p = 0.356), and in PBS + glucose + 100 µM zoledronic acid it was 13.7 ± 7.7 (n = 9, p = 0.447). Thus, exposure to high-doses of zoledronic acid over several hours imposed a statistically insignificant increase in calvarial bone cellular respiration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

Pd phosphor:

Pd(II) complex of meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin

PBS:

Phosphate-buffered saline

MEM:

Minimum essential medium alpha modification

NaCN:

Sodium cyanide

GO:

Glucose oxidase

References

  1. Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367:1714–1723

    Article  PubMed  CAS  Google Scholar 

  2. Reid DM, Devogelaer J-P, Saag K (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 273:1253–1263

    Article  CAS  Google Scholar 

  3. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  PubMed  CAS  Google Scholar 

  4. Balesmans W, Van Wesenbeeck L, Van Hul W (2005) A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int 77:263–274

    Article  CAS  Google Scholar 

  5. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 Suppl:2961–2978

    Article  Google Scholar 

  6. Mönkkönen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, Mönkkönen J (2006) A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 147:437–445

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Evans CE, Braidman IP (1994) Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner 26:95–107

    Article  PubMed  CAS  Google Scholar 

  8. Gasser JS, Ingold P, Venturiere A, Shen V, Green JR (2008) Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 23:544–551

    Article  PubMed  CAS  Google Scholar 

  9. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42:848–860

    Article  PubMed  CAS  Google Scholar 

  10. Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53–62

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Hynes J, Marroquin LD, Hynes J, Marroquin LD, Ogurtsov VI, Christiansen KN, Stevens GJ, Papkovsky DB, Will Y (2006) Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol Sci 92:186–200

    Article  PubMed  CAS  Google Scholar 

  12. Schirrmacher K, Lauterbach S, Bingmann D (1997) Oxygen consumption of calvarial bone cells in vitro. J Orthop Res 15:558–562

    Article  PubMed  CAS  Google Scholar 

  13. Alsamri MT, Al-Shamsi M, Al-Salam S, Marzouqi F, Al-Mansouri A, Al-Hammadi S, Balhaj G, Al Dawaar SK, Al-Hanjeri RS, Benedict S, Sudhadevi M, Conca W, Penefsky HS, Souid A-K (2011) Measurement of oxygen consumption by murine tissues in vitro. J Pharmacol Toxicol Methods 63:196–204

    Article  CAS  Google Scholar 

  14. Casanova M, Herelle J, Thomas M, Softley R, Schindeler A, Little D, Schneider P, Müller R (2016) Effect of combined treatment with zoledronic acid and parathyroid hormone on mouse bone callus structure and composition. Bone 92:70–78

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

Author contributions

The manuscript was written through contributions of all the authors. All the authors have given approval to the final version of the manuscript. The technical assistance of Mr. TP is greatly appreciated.

Corresponding author

Correspondence to Abdul-Kader Souid.

Ethics declarations

Funding sources

This research was supported by a Grant from the United Arab Emirates University.

Conflict of interest

The authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alsamri, M.T., Al-Hammadi, S., Islam, B. et al. Zoledronic acid and bone cellular respiration. J Bone Miner Metab 36, 392–398 (2018). https://doi.org/10.1007/s00774-017-0850-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-017-0850-7

Keywords

Navigation